- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12.24 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Presentation on UMDF Webcast Featuring Clinical Trials in Mitochondrial Disease | 179 | Newsfile | San Diego, California--(Newsfile Corp. - December 10, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol... ► Artikel lesen | |
| 28.11.24 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates | 306 | Newsfile | San Diego, California--(Newsfile Corp. - November 28, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTC: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing... ► Artikel lesen | |
| THIOGENESIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.11.24 | Thiogenesis Therapeutics Corp: Thiogenesis receives patent in Europe | 2 | Stockwatch | ||
| 04.11.24 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Important Core Patent Allowed in Europe | 280 | Newsfile | San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol... ► Artikel lesen | |
| 28.09.24 | Thiogenesis Therapeutics Corp: Thiogenesis hires Triomphe for IR services | 2 | Stockwatch | ||
| 27.09.24 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Investor Relations Engagement | 853 | Newsfile | San Diego, California--(Newsfile Corp. - September 27, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing thiol-active... ► Artikel lesen | |
| 17.09.24 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium | 457 | Newsfile | San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen | |
| 20.08.24 | Thiogenesis Therapeutics Corp: Thiogenesis signs agreement with UCSD | 1 | Stockwatch | ||
| 20.08.24 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program | 229 | Newsfile | San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen | |
| 18.07.24 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Leigh Syndrome Clinical Program | 423 | Newsfile | San Diego, California--(Newsfile Corp. - July 18, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that... ► Artikel lesen | |
| 25.03.24 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS | 345 | Newsfile | San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 47,590 | 0,00 % | Nancy Pelosi kauft Tempus AI - solltest du das ebenfalls? | ||
| QIAGEN | 45,590 | +0,94 % | Qiagen schüttet clever aus | Bei Qiagen profitieren Anleger nicht nur von verbesserten fundamentalen Aussichten: Das Unternehmen schüttet erneut Kapital über einen Reverse Stock Split aus - insgesamt 300 Mio. US-Dollar. Die Venloer... ► Artikel lesen | |
| IMMUNOVANT | 23,590 | -1,17 % | Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential | ||
| SUMMIT THERAPEUTICS | 22,100 | 0,00 % | Here's Why Analysts Are Bullish on Summit Therapeutics Inc. (SMMT) | ||
| APOGEE THERAPEUTICS | 39,460 | 0,00 % | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus... ► Artikel lesen | |
| VERA THERAPEUTICS | 33,700 | 0,00 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,880 | 0,00 % | Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth | ||
| MODERNA | 34,840 | +0,39 % | Moderna-Aktie heute gut behauptet: Aktienwert steigt (34,8633 €) | Am US-amerikanischen Aktienmarkt notiert der Anteilsschein von Moderna aktuell fester. Der jüngste Kurs betrug 36,27 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von Moderna: Das Wertpapier... ► Artikel lesen | |
| BIONTECH | 112,60 | +3,49 % | BioNTech Aktie: Geplante Maßnahmen und Strategien | Die BioNTech-Aktie zeigt sich in den ersten Januarwochen 2025 weitgehend stabil. Am Handelstag des 18. Januar verzeichnete das Papier einen leichten Rückgang von 0,74 Prozent auf 111,93 USD. Die Marktkapitalisierung... ► Artikel lesen | |
| EVOTEC | 7,895 | -0,44 % | Evotec: Verkaufswelle hat begonnen | Der Preis der Evotec-Aktie sinkt. Dieser Kursrückgang findet gesittet statt, ohne dabei die Anleger zu verschrecken. Manch einer hofft noch auf steigende Kurse. Doch das Chartbild spricht eine andere... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,200 | 0,00 % | EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot? | WASHINGTON (dpa-AFX) - Biotech investing is a high-stakes game that may not suit the faint-hearted due to its inherent volatility. However, this sector can offer astronomical returns when investors... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 40,420 | +3,48 % | Harmony Biosciences (NASDAQ:HRMY) Earns Buy Rating from HC Wainwright | ||
| QUANTUM-SI | 2,440 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| JANUX THERAPEUTICS | 40,840 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 30,880 | +6,83 % | Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential |
THIOGENESIS THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THIOGENESIS THERAPEUTICS CORP finden Sie auf Wallstreet Online.
